ELIZABETH TREFZGER: Open Payments
NPI 1629060116 · FRONT ROYAL, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$941 in 37 payments from 10 companies in 2025. Trend: 2023 $374 · 2024 $758 · 2025 $941
Food & beverage: $718Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $354 |
| Neurocrine BioSciences, Inc. | 6 | $118 |
| ABBVIE INC. | 4 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Supernus Pharmaceuticals, Inc. | 5 | $86 |
| Alkermes, Inc. | 4 | $83 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Janssen Pharmaceuticals, Inc | 2 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
Products named: INGREZZA, UZEDY, VRAYLAR, Qelbree, ARISTADA, ABILIFY ASIMTUFII, Auvelity, INVEGA SUSTENNA.
Industry payments across VA — which companies pay providers there.
